Today, the Executive V P& CFO of Omnicell (NASDAQ: OMCL), Kuipers Peter, sold shares of OMCL for $222.3K.
Following Kuipers Peter J.’s last OMCL Sell transaction on June 06, 2018, the stock climbed by 18.4%.
See today’s analyst top recommended stocks >>
Based on Omnicell’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $189 million and quarterly net profit of $6.59 million. In comparison, last year the company earned revenue of $181 million and had a net profit of $837K. OMCL’s market cap is $2.69B and the company has a P/E ratio of 67.43. Currently, Omnicell has an average volume of 300.8K.
Based on 5 analyst ratings, the analyst consensus is Strong Buy with an average price target of $61.00, reflecting a -10.4% downside.
The insider sentiment on Omnicell has been negative according to 68 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Omnicell, Inc. engages in the provision of automation and business analytics software solutions for patient-centric medication and supply management. It operates through Automation and Analytics, and Medication Adherence segments.
